The analysis found:
• UK usage is below the international average in 2012/13 for 11 out of 16 classes of medicines and above in 5
• Between 2008/09 and 2012/13 UK medicines usage per head of total population has risen relative to the international average in 11 classes of medicines and fallen in 5
• For two new sub-classes of medicines – novel oral anti-coagulants and protease inhibitors for hepatitis C – UK usage is less than half of the international average
The analysis was extended to include the two classes with the greatest sales for medicines launched in the last five years, HIV and diabetes:
• UK usage of HIV medicines per head of total population is close to the international average rate
• For new diabetes medicines UK usage per head of is around 1/3rd the international average
• For older diabetes medicines UK usage is significantly above the international average rate
It was beyond the scope of the report to determine the causes of the observed differences in usage between countries.
A complementary report to the OHE analysis published by RAND Europe – commissioned by the Department of Health in England – explores some of those issues in five therapy classes.
Access the OHE analysis here
The accompanying RAND Europe report can be found here